Real World Evidence (RWE)
RWE describes evidence relating to patient health or experience or care delivery collected in the ‘real world’, i.e. outside of controlled research studies. The quality of RWE varies widely and its use is not consistently accepted but it has the potential to reduce uncertainty and improve decision-making.
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
1 December 2006
Objective To model the cost-effectiveness for donors of investing in R&D projects into global diseases via public private partnerships for product development (PD PPPs). Methods We…
Economic Post-Launch Studies: Matching the Desirable with the Feasible
1 September 2006
Whilst companies routinely conduct post-marketing surveillance studies to collect data on adverse events, the focus of this report is on ‘post-launch’ studies conducted to collect information…
Institutions for Industrial Competitiveness in the International Pharmaceutical Industry
3 January 2003
One of the main characteristics of the pharmaceutical industry, including biotechnology, is the important role played by public institutions. Their role is not only focused on…
Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
1 December 2002
Improving the health and life expectancy of the populations of the less developed countries of the world requires both better access to medicines and research and…
Capturing the Unexpected Benefits of Medical Research
5 January 2001
It has long been known that a medicine may turn out to have an unexpected beneficial effect on an illness other than the one it was…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
The UK and Germany are the European leaders in biotechnology. They have many more companies and employees in biotechnology, and much greater sums invested in biotechnology…
Risk and Return in the Pharmaceutical Industry
1 August 1999
This book has been built up from the papers delivered at the Office of Health Economics conference which took place at the Langham Hilton Hotel, London,…
Updating the Cost of a New Chemical Entity
1 February 1999
The objective of this paper is to analyse the existing estimates of NCE costs and look at the subsequent changes in cost components and at the…
Economic Evaluation and Develop Medicines in the Development of Medicines
1 April 1988
In most countries the resources available for health care are increasingly stretched in the face of the competing demands for their use. Therefore health care policy…